Why the study?
Does anti-IFN-gamma monoclonal antibody improve heart contractility in a mouse model of experimental autoimmune myocarditis?
Does anti-IFN-gamma monoclonal antibody improve heart contractility in a mouse model of experimental autoimmune myocarditis?
IFN-gamma released by autoreactive T cells acts similarly to a muscarinic agonist to decrease heart contractility in autoimmune myocarditis, an effect that can be reversed by anti-IFN-gamma antibodies.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for anti-IFN-gamma in autoimmune myocarditis; leaves open translation to human disease.
Experimental autoimmune myocarditis obtained in mice by immunization with heart antigens is characterized by the presence of lymphomononuclear infiltrates in atria and ventricles. Here we show the ability of soluble factors released by immune cells from mice immunized with heart antigens to decrease heart contractility in a similar way to a muscarinic agonist. These effects appear to be mediated by IFN-gamma since all of them could be blocked by an anti-IFN-gamma monoclonal antibody. Moreover, the negative inotropic effect induced by immune cell-conditioned media was blocked by atropine, confirming previous findings that IFN acts as a muscarinic agonist on isolated atria. The role of locally released cytokines and especially of IFN-gamma was also evaluated in infiltrated autoimmune myocarditis hearts; thus, the addition of monoclonal anti-IFN-gamma antibody reversed the decreased contractility characteristics of this model. We conclude that IFN released both systemically and locally by autoreactive T cells may contribute to the impaired cardiac function in this experimental model of autoimmune myocarditis.
No takes yet. Share an insight, caveat, or question.
Pérez-Leirós et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: